Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
25.70
-0.60 (-2.28%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Bicara Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -64.84 | -51.99 | -37.85 |
| Depreciation & Amortization | 0.04 | 0.02 | 0.01 |
| Asset Writedown & Restructuring Costs | 0.57 | 0.57 | - |
| Stock-Based Compensation | 3.47 | 1.9 | 0.81 |
| Other Operating Activities | 13.6 | 13.5 | - |
| Change in Accounts Payable | 1.49 | -8.66 | 5.87 |
| Change in Other Net Operating Assets | -0.39 | -0.96 | -0.92 |
| Operating Cash Flow | -46.06 | -45.63 | -32.08 |
| Capital Expenditures | -0.61 | -0.59 | -0.19 |
| Investing Cash Flow | -0.55 | -0.59 | -0.19 |
| Issuance of Common Stock | 1.55 | 0.15 | 0.16 |
| Financing Cash Flow | 235.48 | 272.5 | 31.7 |
| Net Cash Flow | 188.87 | 226.28 | -0.57 |
| Free Cash Flow | -46.67 | -46.21 | -32.27 |
| Free Cash Flow Per Share | -67.25 | -79.66 | -75.20 |
| Cash Income Tax Paid | 0 | - | 0 |
| Levered Free Cash Flow | - | -32.5 | - |
| Unlevered Free Cash Flow | - | -32.5 | - |
| Change in Net Working Capital | - | 8.9 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.